Book a Demo
Book a Demo
PLATFORM
Support for Tissue Microarray (TMA)

By David Guet, Thomas Le Meur - 05 Feb 2021

For years now, digital pathology has seen the emergence of a plethora of heterogeneous different image types designed for clinical research use or routine diagnostics. Among them one can find tissue microarrays, or TMAs, introduced in the 1990s. TMA images differ from standard histopathological samples; instead of having a whole tissue section on a single slide, we find a large number of tissue cores organized on a grid, from different patients and, possibly from different tissue types. On one TMA slide, we can find several hundred samples.
Technology
New Automatic and Robust Measures to Evaluate Hearing Loss and Tinnitus in Preclinical Models

02 Nov 2020

Background. During this collaboration between CILcare and KeenEye Technologies, a full pipeline has been designed to automatically classify and quantify the number of hair cells in 3D cochlea images.
Deep Learning
Deep Learning-Based Classification of Inherited Retinal Diseases Using Fundus Autofluorescence

01 Oct 2020

Abstract Background. In recent years, deep learning has been increasingly applied to a vast array of ophthalmological diseases. Inherited retinal diseases (IRD) are rare genetic conditions with a distinctive phenotype on fundus autofluorescence imaging (FAF).
Deep Learning
Improving Interpretability of Computer-aided Diagnosis tools on Whole Slide Imaging

01 Sep 2020

For the past decade, the medical and computer science communities have been working together to develop efficient computer-aided decision tools, using technological advances in both fields, to improve research and diagnosis.
Deep Learning
Deep learning AI tools integrated in the Keen Eye™

22 Jul 2020

AI Platform for enterprise-wide tissue analysis and secure clinical research. If you are interested in improving your workflow, simplifying image management and analysis, and learning how enterprise-wide deployment delivers secure and traceable results – subscribe to our webinar!
Biomarker Discovery
Transfer Learning Between Multiple Therapeutic Areas

01 Jul 2020

Many pharmaceutical companies develop their AI capabilities to improve operational efficiencies, scientific research, and the clinical trial process. As for medical image analysis, the complexity and heavy investment of time and effort lead them to turn to specialized partners who possess this expertise. Keen Eye holds a prominent position in this field with significant knowledge inAI, deep learning, and evaluation of large sets of histopathological, diagnostic and molecular images.
Deep Learning
Applications of Deep Learning in Tissue-based Biomarker Analysis for Drug Development

26 Jun 2020

In this webinar you will gain a deeper understanding of what deep learning is, how it works in reproducing pathologist’s expertise in the biomarker analysis of histopathological samples and why this is technology is the key to unlocking the future for biomarker discovery in drug development.
Our Team
An Interview with Keen Eye CTO: Technology that Grows with Business

01 Jun 2020

Keen Eye continues to grow its business in 2020, taking on clients in the pharmaceutical research sector as well as biotechnology partners. This creates new demands on the technology associated with managing projects of an increased scale and reach.
Our Team
BIO US 2020 is still hold in a digital way

01 Jun 2020

Our CEO, Sylvain Berlemont, and our Chief Commercial and Strategic Officer, Jamil Hussain, will be pleased to meet you through the networking platform opening end of April. Our company presentation will be online as well.
Biomarker Discovery
Artificial Intelligence and the fight against cancer: how deep learning aids in lung cancer subtyping

01 May 2020

At the forefront of AI research in medicine are diagnostics and drug development. Deep learning technology allows better decision making, improved efficiency in clinical trials, and a clearer path to drug development.
Load More
10 of 17